Morningstar
•
Mar 20, 2026
Gilead Sciences, Inc.: Gilead: Arcellx Acquisition Shows Conviction in Anito-Cel's Potential Versus J&J's Carvykti
Summary
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acqui
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Moderna, Inc.
May 01, 2026
•
MRNA
Analyst Report: Amgen Inc.
May 01, 2026
•
AMGN
Market Digest: AAPL, AMT, CAKE, FE, KLAC, MGM, MSFT, QCOM, YUM, V, MA
May 01, 2026
•
MSFT, YUM, KLAC, MGM, AAPL, MA, QCOM, V, CAKE, AMT, FE
Analyst Report: QUALCOMM Inc
May 01, 2026
•
QCOM
Analyst Report: Merck & Co., Inc.
May 01, 2026
•
MRK
Analyst Profile
Karen Andersen
Sector Strategist
Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is responsible for biotechnology research.Before joining Morningstar in 2005, Andersen received a master’s degree in business administration from Rice University, where she served as senior healthcare analyst for the M.A. Wright Fund and earned the distinction of Jones Scholar. She has scientific research experience in both academia (at Rice University and the University of Queensland in Australia) and industry (at Lexicon Genetics and a subsidiary of Genzyme).Andersen also holds a bachelor’s degree in biochemistry from Rice University, where she graduated magna cum laude. She is a member of Phi Beta Kappa and holds the Chartered Financial Analyst® designation. She ranked first in the biotechnology industry, and had the highest score overall, in The Wall Street Journal’s annual “Best on the Street” analysts survey in 2013, the last year the survey was conducted.
